Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Mol Cancer Res. 2021 Oct 20;20(2):265–279. doi: 10.1158/1541-7786.MCR-21-0302

Figure 2. GAS6/AXL inhibitor AVB-500 improves response to carboplatin and paclitaxel in ovarian cancer cell lines.

Figure 2.

A, Colony formation assay in cells treated with 0.5 μM Carboplatin (Carbo), 1 μM AVB-500, or a combination of carboplatin and AVB-500 (C+A). Top, representative images; bottom, quantitation of percent to control absorbance at 590nm. Cells were treated for 72 hours and then incubated in media with 10% FBS until vehicle-treated cells formed colonies optimal for visualization. B, Colony formation assay in cells treated with 50 nM Paclitaxel, 1 μM AVB-500, or a combination of paclitaxel and AVB-500 (P+A). Cells were treated for 72 hours and then incubated in media with 10% FBS until vehicle-treated cells formed colonies optimal for visualization. C, Loewe synergism analysis of OVCAR8 and OVCAR3-TPMES cells treated with varying doses of carboplatin and AVB-500.